Pavel Marichal-Gallardo

Dr. Pavel Marichal-Gallardo

Max Planck Institute for Dynamics of Complex Technical Systems
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 February 2017 in Journal of Chromatography A
Verified
Journal Article
Closed access
PMPavel Marichal-Gallardo
Pavel Marichal-Gallardo
MPMichael M. Pieler
Michael M. Pieler
Michael Werner WolffMichael Werner Wolff
Michael Werner Wolff
URUdo Reichl
Udo Reichl

11 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
URUlfert Rand
Ulfert Rand
SKSascha Young Kupke
Sascha Young Kupke
HSHanna Shkarlet
Hanna Shkarlet
MHMarc Dominique Hein
Marc Dominique Hein
THTatjana Hirsch
Tatjana Hirsch
DBDunja Bruder
Dunja Bruder
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) emerged in late 2019 and resulted in a devastating pandemic. Although the first approved vaccines were already administered by the end of 2020, worldwide vaccine availability is still limited. Moreover, immune escape variants of the virus are emerging against which the current vaccines may confer only limited protection. Further, existing antivirals and treatment options against COVID-19 show only limited efficacy. Influenza A virus (IAV) defective interfering particles (DIPs) were previously proposed not only for antiviral treatment of the influenza disease but also for pan-specific treatment of interferon (IFN)-sensitive respiratory virus infections. To investigate the applicability of IAV DIPs as an antiviral for the treatment of COVID-19, we conducted in vitro co-infection experiments with cell culture-derived DIPs and the IFN-sensitive SARS-CoV-2 in human lung cells. We show that treatment with IAV DIPs leads to complete abrogation of SARS-CoV-2 replication. Moreover, this inhibitory effect was dependent on janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling. Further, our results suggest boosting of IFN-induced antiviral activity by IAV DIPs as a major contributor in suppressing SARS-CoV-2 replication. Thus, we propose IAV DIPs as an effective antiviral agent for treatment of COVID-19, and potentially also for suppressing the replication of new variants of SARS-CoV-2.

23 September 2021 in Human Gene Therapy
Verified
Journal Article
Open access
PMPavel Marichal-Gallardo
Pavel Marichal-Gallardo
KBKathleen Börner
Kathleen Börner
MPMichael M. Pieler
Michael M. Pieler
VSVera Sonntag-Buck
Vera Sonntag-Buck
MOMartin Obr
Martin Obr
DGDirk Grimm
Dirk Grimm
We present membrane-based steric exclusion chromatography (SXC) as a universal capture step for purification of adeno-associated virus (AAV) gene transfer vectors independent of their serotype and surface characteristics. SXC is performed by mixing an unpurified cell culture supernatant containing AAV particles with polyethylene glycol (PEG) and feeding the mixture onto a chromatography filter unit. The purified AAV particles are recovered by flushing the unit with a solution lacking PEG. SXC is an inexpensive single-use method that permits to concentrate, purify, and re-buffer AAV particles with yields >95% and >80% impurity clearance. SXC could theoretically be employed at industrial scales with units of nearly 20 m 2 .

1 November 2019 in Vaccine
Verified
Journal Article
Open access
GGGwendal Gränicher
Gwendal Gränicher
JCJuliana Coronel
Juliana Coronel
APAlexander Pralow
Alexander Pralow
PMPavel Marichal-Gallardo
Pavel Marichal-Gallardo
Michael Werner WolffMichael Werner Wolff
Michael Werner Wolff
URUdo Reichl
Udo Reichl
Seasonal and pandemic influenza respiratory infections are still a major public health issue. Vaccination is the most efficient way to prevent influenza infection. One option to produce influenza vaccines is cell-culture based virus propagation. Different host cell lines, such as MDCK, Vero, AGE1.CR or PER.C6 cells have been shown to be a good substrate for influenza virus production. With respect to the ease of scale-up, suspension cells should be preferred over adherent cells. Ideally, they should replicate different influenza virus strains with high cell-specific yields. Evaluation of new cell lines and further development of processes is of considerable interest, as this increases the number of options regarding the design of manufacturing processes, flexibility of vaccine production and efficiency. Here, PBG.PK2.1, a new mammalian cell line that was developed by ProBioGen AG (Germany) for virus production is presented. The cells derived from immortal porcine kidney cells were previously adapted to growth in suspension in a chemically-defined medium. Influenza virus production was improved after virus adaptation to PBG.PK2.1 cells and optimization of infection conditions, namely multiplicity of infection and trypsin concentration. Hemagglutinin titers up to 3.24 log10(HA units/100 µL) were obtained in fed-batch mode in bioreactors (700 mL working volume). Evaluation of virus propagation in high cell density culture using a hollow-fiber based system (ATF2) demonstrated promising performance: Cell concentrations of up to 50 × 106 cells/mL with viabilities exceeding 95%, and a maximum HA titer of 3.93 log10(HA units/100 µL). Analysis of glycosylation of the viral HA antigen expressed showed clear differences compared to HA produced in MDCK or Vero cell lines. With an average cell-specific productivity of 5000 virions/cell, we believe that PBG.PK2.1 cells are a very promising candidate to be considered for next-generation influenza virus vaccine production.

23 December 2020 in ChemCatChem
Verified
Journal Article
Open access
PDF file
RMReza Mahour
Reza Mahour
PMPavel Marichal-Gallardo
Pavel Marichal-Gallardo
TRThomas Rexer
Thomas Rexer
URUdo Reichl
Udo Reichl
Recombinant Leloir glycosyltransferases can be exploited to synthesize a wide range of HMOs using in vitro biocatalytic reactions. However, high costs and unavailability of bulk amounts of most nucleotide sugars, such as guanosine diphosphate L‐fucose (GDP‐Fuc), are major obstacles for the efficient large‐scale synthesis. Here, we report two novel multi‐enzyme cascades for the synthesis of GDP‐Fuc from readily available and low cost precursors. The first cascade was developed to produce GDP‐Fuc from guanosine (Guo), fucose (Fuc), polyphosphate (PolyPn) and catalytic amounts of adenine triphosphate (ATP). GDP‐Fuc was produced with a final concentration of 7 mM (4.1 g/L) and a reaction yield of 68 % from Guo and Fuc within 48 h with a biocatalyst load of 0.34 genzyme/gproduct. A second cascade, consisting of ten enzymes and eleven reactions was developed to carry out the synthesis from mannose (Man), Guo, PolyPn, L‐glutamine (L‐Glu) and catalytic amounts of ATP, and nicotinamide adenine dinucleotide phosphate (NADPH). Utilizing this cascade, GDP‐Fuc was produced with a final concentration of 7.6 mM (4.5 g/L) and a reaction yield of 72 % in a reaction time of 48 h with a biocatalyst load of 0.97 genzyme/gproduct. Finally, a method for chromatographic purification of GDP‐Fuc was established achieving product purities of 90.5 %.